60 minutes
Breaking News from CTAD 2025: What Canadian HCPs Need to Know
This episode is part of a series. Click here to view the entire series.
Join leading experts Dr. Sharon Cohen, Dr. Marwan Sabbagh, and Dr. Alireza Atri for a fast-paced CTAD 2025 briefing tailored for Canadian clinicians. Gain clear, practice-focused insights on emerging therapies, biomarkers, and how new data may shape Alzheimer’s care in Canada.
Learning Objectives:
Evaluate emerging evidence on semaglutide and lecanemab and identify how these findings may inform treatment decisions and safety considerations in Canadian practice
Assess the performance and appropriate use of blood-based biomarkers and understand their role in patient selection and clinical trial recruitment
Discuss how new CTAD 2025 data can be integrated into the Canadian Alzheimer’s care landscape, including practical considerations for implementation
